Abstract
FVB/N wild type and transgenic HER-2/neu FVB/N female mice breed at N.N. Petrov Research Institute of Oncology were under observation until natural death without any special treatment. Age-related dynamics of body weight, food consumption and parameters of carbohydrate and lipid metabolism, level of nitric oxide, malonic dialdehyde, catalase, Cu, Zn-superoxide dismutase, vascular endothelial growth factor were studied in both mice strains. The parameters of life span and tumor pathology were studied as well. Cancer-prone transgenic HER-2/neu mice developed in 100 % multiple mammary adenocarcinomas and died before the age of 1 year. Forty tree percent of long-lived wild type mice survived the age of 2 years and 19 %—800 days. The total tumor incidence in wild type mice was 34 %. The age-associated changes in the level of serum IGF-1, glucose and insulin started much earlier in transgene HER-2/neu mice as compared with wild type FVB/N mice. It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis.
Similar content being viewed by others
References
Anisimov VN (2001) Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. Mech Ageing Dev 122(12):1221–1255
Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40(8–9):685–693
Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MV, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA (2010a) Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9(1):188–197
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV (2010b) Rapamycin extends maximal life span in cancer-prone mice. Am J Pathol 176(5):1092–1096
Anisimov VN, Popovich IG, Zabezhinski MA (2013) Methods of testing pharmacological drugs effects on aging and life-span in mice. Methods Mol Biol 1048:145–160
Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, Mancini R, Franceschi C (2001) The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuroendocrinol Lett 22(6):441–447
Bazhanova ED, Molodsov VN, Popovich IG, Anisimov VN (2007) Apoptosis regulation in hypothalamic neurosceretory cells of hER2/neu transgenic mice in ontogenesis. Adv Gerontol 20(4):31–35
Goubler EV (1978) Computing methods of pathology analysis and recognition. Meditsina, Leningrad
Gupta K, Krishnaswamy G, Karnad A, Peiris AN (2002) Insulin: a novel factor in carcinogenesis. Am J Med Sci 323(3):140–145
Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135(1):55–62. doi:10.1043/2010-0454-RAR.1
Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH (1993) FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14(11):2353–2358
Huang P, Duda DG, Jain RK, Fukumura D (2008) Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med 5(3):253–263
Ingram DK, Jucker M (1999) Developing mouse models of aging: a consideration of strain differences in age-related behavioral and neural parameters. Neurobiol Aging 20(2):137–415
Liao C-Y, Kennedy BK (2014) Mouse models and aging: longevity and progeria. Curr Topics Dev Biol 109:249–285
Mahler JM, Stokes W, Mann PC, Takaoka M, Maronpot RR (1996) Spontaneous lesions in aging FVB/N mice (1996). Toxicol Pathol 24(6):710–716
Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54(1):105–115
Muller WJ, Ho J, Siegel PM (1998) Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer. Biochem Soc Symp 63:149–157
Nadon NL (2006) Exploiting the rodent model for studies on the pharmacology of lifespan extension. Aging Cell 5(1):9–15
Pierpaoli E, Viola V, Barucca A, Orlando F, Galli F, Provinciali M (2013) Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice. Carcinogenesis 34(6):1352–1360
Raafat A, Strizzi L, Lashin K, Ginsburg E, McCurdy D, Salomon D, Smith GH, Medina D, Callahan R (2012) Effects of age and parity on mammary gland lesions and progenitor cells in the FVB/N-RC mice. PLoS One 7(8):e43624
Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD (2009) Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol 46(4):736–745. doi:10.1354/vp.08-VP-0280-R-FL
Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT et al (1991) FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 88(6):2065–2069
Turusov VS, Mohr U (eds) (1994) Pathology of tumours in laboratory animals. Tumours of the mouse, IARC Sci Publ No 111, 2nd edn. IARC, Lyon
Wakefield LM, Thordarson G, Nieto AI, Shyamala G, Galvez JJ, Anver MR, Cardiff RD (2003) Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med 53(4):424–432
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Panchenko, A.V., Popovich, I.G., Trashkov, A.P. et al. Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB/N female mice. Biogerontology 17, 317–324 (2016). https://doi.org/10.1007/s10522-015-9611-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10522-015-9611-y